← Back to Search

Immunostimulant

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Phase 1 & 2
Waitlist Available
Research Sponsored by Altor BioScience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.

Eligible Conditions
  • Indolent B Cell Non-Hodgkin Lymphomas

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg
Number of Participants With Treatment Emergent Adverse Events
Overall Response Rate
Secondary study objectives
Blood Cell Counts
Duration of Response
Immunogenicity
+7 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

9Treatment groups
Experimental Treatment
Group I: Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kgExperimental Treatment2 Interventions
Group II: Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgExperimental Treatment2 Interventions
Group III: Phase 1 Cohort 7: N-803 - SQ 20 ug/kgExperimental Treatment2 Interventions
Group IV: Phase 1 Cohort 6: N-803 - SQ 15 ug/kgExperimental Treatment2 Interventions
Group V: Phase 1 Cohort 5: N-803 - SQ 10 ug/kgExperimental Treatment2 Interventions
Group VI: Phase 1 Cohort 4: N-803 - SQ 6 ug/kgExperimental Treatment2 Interventions
Group VII: Phase 1 Cohort 3: N-803 - IV 6 ug/kgExperimental Treatment2 Interventions
Group VIII: Phase 1 Cohort 2: N-803 - IV 3 ug/kgExperimental Treatment2 Interventions
Group IX: Phase 1 Cohort 1: N-803 - IV 1 ug/kgExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
N-803
2021
Completed Phase 2
~130
Rituximab
FDA approved

Find a Location

Who is running the clinical trial?

Altor BioScienceLead Sponsor
17 Previous Clinical Trials
478 Total Patients Enrolled
~4 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top